SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
RLMD reported Third quarter ended September 30, 2026 results. The stock moved +1.2% on the print.
RLMDearnings

Earnings reactions, page 3

Relmada Therapeutics, Inc. (RLMD) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Research and development expense for the three months ended September 30, 2026, totaled $9.2 million.
  • General and administrative expense for the three months ended September 30, 2026, totaled $3.9 million.
  • Net cash used in operating activities for the three months ended September 30, 2026, totaled $12.6 million.
  • The net loss for the three months ended September 30, 2026, was $13.9 million, or $0.12 per basic and diluted share.
  • Cash, cash equivalents and short-term investments of approximately $202.1 million as of September 30, 2026.

Guidance

  • Company operations expected to be funded through 2029.
  • NDV-01 United States IND submission expected by year-end 2026.
  • Sepranolone United States IND submission expected by year-end 2026.

Price and volatility reaction

The stock moved +1.2% on the print. No front-expiry chain was on file, so there is no straddle expected move.

MeasureValueBasis
Close before release4.162026-11-12
Close after release4.212026-11-13
Realised move+1.2%close to close
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →